These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 28403766)
1. Controversies in diagnosis and management of community-acquired pneumonia. Sparham S; Charles PG Med J Aust; 2017 Apr; 206(7):316-319. PubMed ID: 28403766 [TBL] [Abstract][Full Text] [Related]
2. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559 [TBL] [Abstract][Full Text] [Related]
3. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program. Gotfried MH Am J Med; 2001 Dec; 111 Suppl 9A():25S-29S; discussion 36S-38S. PubMed ID: 11755440 [TBL] [Abstract][Full Text] [Related]
4. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia. Goldstein LH; Gabin A; Fawaz A; Freedberg NA; Schwartz N; Elias M; Saliba W Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1042-8. PubMed ID: 26238864 [TBL] [Abstract][Full Text] [Related]
5. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274 [TBL] [Abstract][Full Text] [Related]
6. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. Corrales-Medina VF; Suh KN; Rose G; Chirinos JA; Doucette S; Cameron DW; Fergusson DA PLoS Med; 2011 Jun; 8(6):e1001048. PubMed ID: 21738449 [TBL] [Abstract][Full Text] [Related]
7. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Corrales-Medina VF; Musher DM; Wells GA; Chirinos JA; Chen L; Fine MJ Circulation; 2012 Feb; 125(6):773-81. PubMed ID: 22219349 [TBL] [Abstract][Full Text] [Related]
8. Risk stratification for cardiac complications in patients hospitalized for community-acquired pneumonia. Corrales-Medina VF; Taljaard M; Fine MJ; Dwivedi G; Perry JJ; Musher DM; Chirinos JA Mayo Clin Proc; 2014 Jan; 89(1):60-8. PubMed ID: 24388023 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954 [TBL] [Abstract][Full Text] [Related]
10. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae. Yayan J Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917 [TBL] [Abstract][Full Text] [Related]
11. A case-based approach to evaluating azithromycin use and cardiovascular risks. Wong E; Nguyen TV Consult Pharm; 2014 Jan; 29(1):47-52. PubMed ID: 24413014 [TBL] [Abstract][Full Text] [Related]
12. [Corticosteroids in community acquired pneumonia: Where are we in 2018?]. Soumagne T; Rabbat A Rev Mal Respir; 2018 Oct; 35(8):813-827. PubMed ID: 30217573 [TBL] [Abstract][Full Text] [Related]
13. Management of community-acquired pneumonia by trained family general practitioners. Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872 [TBL] [Abstract][Full Text] [Related]
14. Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia. Sibila O; Laserna E; Maselli DJ; Fernandez JF; Mortensen EM; Anzueto A; Waterer G; Restrepo MI Respirology; 2015 May; 20(4):660-6. PubMed ID: 25776134 [TBL] [Abstract][Full Text] [Related]
15. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448 [TBL] [Abstract][Full Text] [Related]
16. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Weiss K; Tillotson GS Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190 [TBL] [Abstract][Full Text] [Related]
17. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Skalsky K; Yahav D; Lador A; Eliakim-Raz N; Leibovici L; Paul M Clin Microbiol Infect; 2013 Apr; 19(4):370-8. PubMed ID: 22489673 [TBL] [Abstract][Full Text] [Related]
18. Importance of functional assessment in the management of community-acquired and healthcare-associated pneumonia. Kosai K; Izumikawa K; Imamura Y; Tanaka H; Tsukamoto M; Kurihara S; Takazono T; Morinaga Y; Nakamura S; Miyazaki T; Yanagihara K; Tashiro T; Kohno S Intern Med; 2014; 53(15):1613-20. PubMed ID: 25088872 [TBL] [Abstract][Full Text] [Related]
19. Community-acquired pneumonia with risk for drug-resistant pathogens. Fleming V; Buck B; Nix N; Kumar P; Southwood R South Med J; 2013 Mar; 106(3):209-16. PubMed ID: 23462490 [TBL] [Abstract][Full Text] [Related]